Edgewise Therapeutics, Inc. (EWTX)

NASDAQ

$23.95

+$0.33 (1.40%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$23.01$24.31

Open $23.67

52 Week Range

$10.60$35.50

Previous Close $23.62

Market Cap2.54B

Volume1.78M

Avg Volume1.07M

P/E (TTM)-16.68

EPS (TTM)$-1.44

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Edgewise Therapeutics, Inc.

DEC22025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Source: PRNewsWire•13 days ago

BOULDER, Colo. , Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac con...

NOV202025

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Source: PRNewsWire•25 days ago

BOULDER, Colo. , Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors....

NOV122025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Source: PRNewsWire•33 days ago

BOULDER, Colo. , Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac co...

NOV102025

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Source: PRNewsWire•35 days ago

BOULDER, Colo. , Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the ...

NOV72025

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Source: PRNewsWire•38 days ago

BOULDER, Colo. , Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences: Guggenheim 2nd Annu...

NOV62025

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Source: PRNewsWire•39 days ago

– Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch – – MESA open-label extension trial of sevasemten in Becker muscular dystrophy continues to enroll...

NOV32025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Source: PRNewsWire•42 days ago

BOULDER, Colo. , Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac con...

OCT22025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Source: PRNewsWire•74 days ago

BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac con...

OCT22025

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Source: PRNewsWire•74 days ago

BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle Society (WM...